Stephen P. Letrent

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski et al. · Journal of Clinical Oncology · 2012 · 265 citations · Full text

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Pasi A. Jänne, David S. Boss, D. Ross Camidge et al. · Clinical Cancer Research · 2011 · 180 citations · Full text

Effects of a Potent and Specific P-Glycoprotein Inhibitor on the Blood-Brain Barrier Distribution and Antinociceptive Effect of Morphine in the Rat

Stephen P. Letrent, Gary M. Pollack, Kenneth R. Brouwer et al. · Drug Metabolism and Disposition · 1999 · 169 citations

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge et al. · Cancer · 2014 · 142 citations · Full text

Increased brain P-glycoprotein in morphine tolerant rats

Christina L. Aquilante, Stephen P. Letrent, Gary M. Pollack et al. · Life Sciences · 1999 · 112 citations

Molecular Pharmacology, Molecular Neuroscience, Neurophysiology +8